永顺生物 — Investor Relations & Filings
About 永顺生物
Guangdong Winsun Bio-Pharmaceutical Co., Ltd. is a specialized enterprise focused on the research, development, production, and distribution of veterinary biological products. The company primarily develops vaccines for livestock and poultry, with a significant emphasis on swine and avian health. Its product portfolio includes live and inactivated vaccines targeting major diseases such as classical swine fever, porcine reproductive and respiratory syndrome (PRRS), and avian influenza. Winsun Bio-Pharmaceutical leverages advanced biotechnology to provide comprehensive animal disease prevention and control solutions. The company maintains a strong focus on technological innovation and quality management, operating multiple GMP-certified production lines to ensure the efficacy and safety of its biological preparations. Its research initiatives often involve collaborations with academic institutions to advance veterinary medicine and support the animal husbandry sector.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 公司章程 | 2026-04-27 | Chinese | |
| 董事会薪酬与考核委员会关于2024年股权激励计划第一个解除限售期解除限售条件成就及回购注销部分限制性股票方案的核查意见 | 2026-04-27 | Chinese | |
| 关于2024年股权激励计划第一个解除限售期解除限售条件成就的公告 | 2026-04-27 | Chinese | |
| 关于购买公司及董事、高级管理人员责任险的公告 | 2026-04-27 | Chinese | |
| 2025年年度权益分派预案公告 | 2026-04-27 | Chinese | |
| 拟续聘2026年度会计师事务所公告 | 2026-04-27 | Chinese |
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
15 filings
| |||||
| 40071957 | 公司章程 | 2026-04-27 | Chinese | ||
| 40071950 | 董事会薪酬与考核委员会关于2024年股权激励计划第一个解除限售期解除限售条件成就及回购注销部分限制性股票方案的核查意见 | 2026-04-27 | Chinese | ||
| 40071943 | 关于2024年股权激励计划第一个解除限售期解除限售条件成就的公告 | 2026-04-27 | Chinese | ||
| 40071935 | 关于购买公司及董事、高级管理人员责任险的公告 | 2026-04-27 | Chinese | ||
| 40071921 | 2025年年度权益分派预案公告 | 2026-04-27 | Chinese | ||
| 40071915 | 拟续聘2026年度会计师事务所公告 | 2026-04-27 | Chinese | ||
| 40071910 | 关于召开2025年年度股东会通知公告(提供网络投票) | 2026-04-27 | Chinese | ||
| 40071905 | 董事会关于独立董事独立性自查情况的专项报告 | 2026-04-27 | Chinese | ||
| 40071896 | 董事会审计委员会关于2024年股权激励计划第一个解除限售期解除限售条件成就及回购注销部分限制性股票方案的核查意见 | 2026-04-27 | Chinese | ||
| 40071892 | 关于调整2024年股权激励计划回购价格的公告 | 2026-04-27 | Chinese | ||
| 40071887 | 天健会计师事务所(特殊普通合伙)关于广东永顺生物制药股份有限公司非经营性资金占用及其他关联资金往来情况的专项审计说明 | 2026-04-27 | Chinese | ||
| 40071811 | 内部控制自我评价报告 | 2026-04-27 | Chinese | ||
| 40071802 | 董事、高级管理人员薪酬管理制度 | 2026-04-27 | Chinese | ||
| 40071798 | 广东君信经纶君厚律师事务所关于广东永顺生物制药股份有限公司2024年股权激励计划第一次解除限售、调整回购价格并回购注销部分限制性股票的法律意见书 | 2026-04-27 | Chinese | ||
| 40071776 | 2026年一季度报告 | 2026-04-27 | Chinese | ||
Market data
Market data not available
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
13260917 Canada Inc.
Biotech developing oral small molecules to restore muscle s…
|
MSCL | CA | Manufacturing |
|
1608557 Ontario Inc.
Biopharmaceutical company dedicated to R&D, discovery, and …
|
OTROQ | CA | Manufacturing |
|
3B BlackBio Dx Limited
Develops molecular diagnostic kits for oncology, infectious…
|
3BBLACKBIO | IN | Manufacturing |
|
3D Medicines Inc.
Commercial-stage biopharma specializing in next-generation …
|
1244 | HK | Manufacturing |
|
3SBio Inc.
Biopharmaceutical enterprise specializing in R&D, productio…
|
1530 | KY | Manufacturing |
|
4BASEBIO PLC
Manufactures GMP-grade synthetic DNA for next-generation th…
|
4BB | GB | Manufacturing |
|
4D Molecular Therapeutics, Inc.
Develops genetic medicines using AAV vectors for ophthalmol…
|
FDMT | US | Manufacturing |
|
4Front Ventures Corp.
Vertically integrated cannabis operator managing cultivatio…
|
FFNT | CA | Manufacturing |
|
4SC AG
Biopharmaceutical company with no products under developmen…
|
VSC | DE | Manufacturing |
|
60 DEGREES PHARMACEUTICALS, INC.
Develops and commercializes medicines for infectious diseas…
|
SXTP | US | Manufacturing |
永顺生物 via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/58908/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=58908 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=58908 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=58908 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 58908}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for 永顺生物 (id: 58908)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.